首页> 外文期刊>Tropical Medicine and International Health: TM and IH >Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria.
【24h】

Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria.

机译:奎宁药代动力学:在健康的白种人受试者和恶性疟疾患者中的耳毒性和心脏毒性作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To study the pharmacokinetic behaviour of quinine in Caucasians with and without malaria. METHOD: Quinine-dihydrochloride was administered intravenously as a single dose of 300 mg to 12 healthy subjects and as multiple doses of 600 mg in 4 h every 8 h in 10 patients with falciparum malaria. Plasma quinine concentrations were measured by high-performance liquid chromatography RESULTS: Quinine pharmacokinetics are time-dependent: the apparent elimination halftime is shorter in the accumulation phase than in the elimination phase; in malaria patients the maximal quinine concentration was reached in half the time calculated on the basis of the elimination phase after the last quinine infusion. Nevertheless a loading dose seemed advisable to reach adequate therapeutic levels quickly. In malaria patients the highest plasma concentrations during or at the end of the infusions were positively correlated with body weight. There was no correlation between body weight and the volume of distribution of quinine as calculated during the elimination phase. Hearing loss was audiometrically documented in 9 healthy subjects at a mean maximal plasma quinine concentration of only 2 mg/l. All malaria patients suffered serious cochlear hearing impairment. The ototoxic effects in both healthy subjects and patients appeared to be reversible. No electrographic changes were noted in the healthy subjects, whereas a clinically insignificant mean lengthening of the corrected QT interval was seen in the malaria patients. CONCLUSION: Intravenous quinine pharmacokinetics in healthy Caucasians were similar to those reported for Nigerian or Thai subjects. At effective doses quinine causes considerable but reversible cochlear hearing losses in both healthy persons and in patients. Our findings do support the need for a loading dose. The fact that in malaria patients there was no correlation between body weight and quinine VD as calculated during the elimination phase renders questionable the usefulness of dosing quinine according to body weight.
机译:目的:研究奎宁在有或没有疟疾的白种人中的药代动力学行为。方法:对10例恶性疟疾患者,静脉注射奎宁-二盐酸盐300毫克单剂量,对12位健康受试者静脉注射,每4小时600毫克多剂量。结果:奎宁的药代动力学是时间依赖性的:在积累阶段的表观消除半衰期比在消除阶段要短。在疟疾患者中,在最后一次奎宁输注后的消除阶段基础上,达到最大奎宁浓度的时间缩短了一半。尽管如此,建议增加剂量以迅速达到足够的治疗水平。在疟疾患者中,输注期间或结束时的最高血浆浓度与体重呈正相关。在消除阶段计算出的体重与奎宁的分布量之间没有相关性。在9名健康受试者中,平均最大血浆奎宁浓度仅为2 mg / l,听力测听记录了听力损失。所有疟疾患者均患有严重的耳蜗听力障碍。健康受试者和患者的耳毒性作用似乎都是可逆的。在健康受试者中未发现电图变化,而在疟疾患者中未见校正QT间隔的临床平均延长。结论:健康白种人中的奎宁静脉药代动力学与尼日利亚或泰国受试者的相似。在有效剂量下,奎宁会对健康人和患者造成可观但可逆的耳蜗听力损失。我们的发现确实支持需要加药剂量。在消除疟疾的阶段,疟疾患者的体重与奎宁VD之间没有相关性,这一事实使根据体重服用奎宁的有效性产生了疑问。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号